Protalix BioTherapeutics Announces First Patient Dosed in the AIR DNase™ Phase II Clinical Trial for Cystic Fibrosis
July 07, 2016 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, July 07, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today the first patient has been dosed in the Company’s phase II clinical...
Protalix BioTherapeutics Initiates PRX-102 Global Phase III Clinical Trial of Fabry Disease to Support United States and European Filings
June 06, 2016 07:00 ET
|
Protalix BioTherapeutics, Inc.
24-Month Superiority Trial vs. Fabrazyme® for a United States Filing At 12 Months, Interim Analysis of the Superiority Trial Data will be Performed to Test for Non-Inferiority Compared to Fabrazyme...
Protalix BioTherapeutics to Present at the Jefferies 2016 Global Healthcare Conference
June 02, 2016 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, June 02, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today announced that Moshe Manor, the Company's President and Chief Executive...
Protalix BioTherapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update
May 09, 2016 07:00 ET
|
Protalix BioTherapeutics, Inc.
Advanced Discussions with FDA regarding SPA for Phase III Clinical Trial of PRX-102 Expected to Commence around Mid-Year Phase II Clinical Trial of PRX-110 in Cystic Fibrosis Patients to...
Protalix BioTherapeutics Reports Fiscal Year 2015 Financial Results and Provides Corporate Update
March 08, 2016 07:32 ET
|
Protalix BioTherapeutics, Inc.
Net Income of $58 Million Generated mainly due to the Sale of Our Share in Collaboration to Pfizer Strong Cash Position of $76.3 Million Projected to Fund Operations into 2018 Special...
Protalix BioTherapeutics Presents Positive Six and Twelve Month Interim Clinical Data on PRX-102 for the Treatment of Fabry Disease at the 12th Annual WORLDSymposium™ 2016
March 03, 2016 07:00 ET
|
Protalix BioTherapeutics, Inc.
Demonstrated Effectiveness Across All Disease Parameters Including Cardiac and Kidney FunctionsPRX-102 Safe and Well Tolerated With Very Low Formation of AntibodiesCARMIEL, Israel, March 03, 2016 ...
Protalix BioTherapeutics to Participate in the SunTrust Robinson Humphrey Orphan Drug Day and the 12th Annual WORLDSymposium™ 2016
February 22, 2016 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Feb. 22, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) and (TASE:PLX), announced today that the Company will participate in the SunTrust Robinson Humphrey...
Protalix BioTherapeutics to Conduct Phase III Clinical Trial for PRX-102 for the Treatment of Fabry Disease Following a Successful End-of-Phase II Meeting With FDA
November 16, 2015 07:00 ET
|
Protalix BioTherapeutics, Inc.
Clear Path for Biologics License Application (BLA) Submission
One Short-Term Safety and Efficacy Study Required to Support Full Approval
In Parallel, Protalix to Conduct Phase III Head-to-Head...
Protalix BioTherapeutics Reports Third Quarter 2015 Financial Results
November 09, 2015 16:05 ET
|
Protalix BioTherapeutics, Inc.
Net losses narrowed
Recent sale of Company's Share in Collaboration and Equity Issuance to Pfizer Yielding a Total of $46 Million to Help Aggressively Push all Three Product...
Protalix BioTherapeutics Reports Positive Long Term Data on PRX-102 for Fabry Disease
October 19, 2015 07:30 ET
|
Protalix BioTherapeutics, Inc.
Significantly Improved PK Characteristics Result in:
Higher Active Enzyme Quantities, Induced Immune Tolerance
Meaningful Clinical Benefit Demonstrated Across All Key Disease Parameters...